M A Shokri1, T Moghadam Fard2, T Ramim3, A Hejrati4, L Hejrati5, M Mokhtare6. 1. School of medicine, Iran University of medical sciences, Tehran, Iran. Electronic address: MohammadAliShokri@yahoo.com. 2. School of medicine, Iran University of medical sciences, Tehran, Iran. Electronic address: Tina_Mfd@yahoo.com. 3. Department of Health Information Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Ramim.t@iums.ac.ir. 4. Internal Medicine Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: alireza.hejrati@gmail.com. 5. School of medicine, Iran University of medical sciences, Tehran, Iran. Electronic address: Lina1381@gmail.com. 6. Internal Medicine Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: marjanmokhtare@yahoo.com.
Abstract
OBJECTIVE: Proton pump inhibitors (PPI) are among the most prescribed drugs worldwide; therefore, assessing their effect on COVID-19 infection symptoms and severity is of great importance. This study was designed to evaluate the role of previous PPI consumption on the clinical presentation and severity of COVID-19. PATIENTS AND METHODS: All adult COVID-19 patients were eligible in this observational cross-sectional study. The patients' demographic and clinical data, history of PPI consumption, and comorbid disease were recorded. Charlson comorbidity index (CCI) and quick COVID-19 severity index (qCSI) score were calculated for each patient. IBM SPSS version 25 was used for statistical analysis. RESULTS: Totally 670 patients completed the study (PPI users=121). The average severity (qCSI) score of PPI user patients with comorbidity score of zero was significantly higher than non-users (P-value=0.001). Mortality rate was 6.6% and 3.8% in PPI-users and non-users respectively (P-value=0.117). PPI users were significantly more symptomatic compared to non-users (P-value=0.001). CONCLUSION: We found that PPI users were meaningfully more symptomatic and had a higher severity (qCSI) score. Rational prescription of PPIs should be considered by physicians during and after the pandemic.
OBJECTIVE: Proton pump inhibitors (PPI) are among the most prescribed drugs worldwide; therefore, assessing their effect on COVID-19 infection symptoms and severity is of great importance. This study was designed to evaluate the role of previous PPI consumption on the clinical presentation and severity of COVID-19. PATIENTS AND METHODS: All adult COVID-19 patients were eligible in this observational cross-sectional study. The patients' demographic and clinical data, history of PPI consumption, and comorbid disease were recorded. Charlson comorbidity index (CCI) and quick COVID-19 severity index (qCSI) score were calculated for each patient. IBM SPSS version 25 was used for statistical analysis. RESULTS: Totally 670 patients completed the study (PPI users=121). The average severity (qCSI) score of PPI user patients with comorbidity score of zero was significantly higher than non-users (P-value=0.001). Mortality rate was 6.6% and 3.8% in PPI-users and non-users respectively (P-value=0.117). PPI users were significantly more symptomatic compared to non-users (P-value=0.001). CONCLUSION: We found that PPI users were meaningfully more symptomatic and had a higher severity (qCSI) score. Rational prescription of PPIs should be considered by physicians during and after the pandemic.
Keywords:
COVID-19 severity; COVID-19 symptoms; Gravité du COVID-19; Les inhibiteurs de la pompe à protons; Mortality; Mortalité; Predictor; Proton pump inhibitors; Prédicteur; Symptômes du COVID-19
Authors: Jennifer Lighter; Michael Phillips; Sarah Hochman; Stephanie Sterling; Diane Johnson; Fritz Francois; Anna Stachel Journal: Clin Infect Dis Date: 2020-07-28 Impact factor: 9.079
Authors: Giacomo Grasselli; Massimiliano Greco; Alberto Zanella; Giovanni Albano; Massimo Antonelli; Giacomo Bellani; Ezio Bonanomi; Luca Cabrini; Eleonora Carlesso; Gianpaolo Castelli; Sergio Cattaneo; Danilo Cereda; Sergio Colombo; Antonio Coluccello; Giuseppe Crescini; Andrea Forastieri Molinari; Giuseppe Foti; Roberto Fumagalli; Giorgio Antonio Iotti; Thomas Langer; Nicola Latronico; Ferdinando Luca Lorini; Francesco Mojoli; Giuseppe Natalini; Carla Maria Pessina; Vito Marco Ranieri; Roberto Rech; Luigia Scudeller; Antonio Rosano; Enrico Storti; B Taylor Thompson; Marcello Tirani; Pier Giorgio Villani; Antonio Pesenti; Maurizio Cecconi Journal: JAMA Intern Med Date: 2020-10-01 Impact factor: 21.873
Authors: Jose L Blanco; Juan Ambrosioni; Felipe Garcia; Esteban Martínez; Alex Soriano; Josep Mallolas; Jose M Miro Journal: Lancet HIV Date: 2020-04-15 Impact factor: 12.767
Authors: Jaroslava Raudenská; Veronika Steinerová; Alena Javůrková; Ivan Urits; Alan D Kaye; Omar Viswanath; Giustino Varrassi Journal: Best Pract Res Clin Anaesthesiol Date: 2020-07-18
Authors: Seung Won Lee; Eun Kyo Ha; Abdullah Özgür Yeniova; Sung Yong Moon; So Young Kim; Hyun Yong Koh; Jee Myung Yang; Su Jin Jeong; Sun Joon Moon; Joo Young Cho; In Kyung Yoo; Dong Keon Yon Journal: Gut Date: 2020-07-30 Impact factor: 31.793